XmAb541, a Claudin 6-Targeted Bispecific Antibody Therapy for Targeting Solid Tumors
Time: 9:30 am
day: Conference Day 1
Details:
- Preclinical development of XmAb541, a CLDN6 x CD3 bispecific antibody for selective targeting of CLDN6 expressing tumors
